Marksans Pharma Limited has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.
MARKSANS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.5 pts more than Nifty Microcap 250 and 0.5 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Marksans Pharma has submitted to the exchange a disclosure under Regulation 31(4) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. This is a periodic, SEBI-mandated filing in which promoters report their aggregate shareholding along with details of any encumbrances (such as pledges or liens) on their shares. The headline does not specify any change in pledge levels, creation of new encumbrances, or any movement in promoter or FII holdings. No transaction-level numbers or comparative figures are provided in the headline itself.
This appears to be a routine compliance disclosure and, on its own, carries no clear positive or negative implication for shareholders. Investors should review the actual disclosure document on the BSE/NSE portal to check for any meaningful change in promoter pledging or stake movement before drawing conclusions.